ATE396171T1 - Acylierte 6,7,8,9-tetrahydro-5h- benzocycloheptenyl-amine und deren pharmazeutische verwendung - Google Patents

Acylierte 6,7,8,9-tetrahydro-5h- benzocycloheptenyl-amine und deren pharmazeutische verwendung

Info

Publication number
ATE396171T1
ATE396171T1 AT02722069T AT02722069T ATE396171T1 AT E396171 T1 ATE396171 T1 AT E396171T1 AT 02722069 T AT02722069 T AT 02722069T AT 02722069 T AT02722069 T AT 02722069T AT E396171 T1 ATE396171 T1 AT E396171T1
Authority
AT
Austria
Prior art keywords
acylated
tetrahydro
pharmaceutical use
benzocycloheptenyl
amine
Prior art date
Application number
AT02722069T
Other languages
English (en)
Inventor
Hartmut Strobel
Paulus Wohlfart
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of ATE396171T1 publication Critical patent/ATE396171T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/54—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/74—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
AT02722069T 2001-02-13 2002-02-12 Acylierte 6,7,8,9-tetrahydro-5h- benzocycloheptenyl-amine und deren pharmazeutische verwendung ATE396171T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01102853 2001-02-13

Publications (1)

Publication Number Publication Date
ATE396171T1 true ATE396171T1 (de) 2008-06-15

Family

ID=8176424

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02722069T ATE396171T1 (de) 2001-02-13 2002-02-12 Acylierte 6,7,8,9-tetrahydro-5h- benzocycloheptenyl-amine und deren pharmazeutische verwendung

Country Status (33)

Country Link
US (2) US6759412B2 (de)
EP (1) EP1362027B1 (de)
JP (1) JP4319836B2 (de)
KR (1) KR100975781B1 (de)
CN (1) CN1296346C (de)
AR (1) AR035431A1 (de)
AT (1) ATE396171T1 (de)
AU (1) AU2002253012B2 (de)
BG (1) BG108060A (de)
BR (1) BR0207197A (de)
CA (1) CA2438324C (de)
CZ (1) CZ20032134A3 (de)
DE (1) DE60226704D1 (de)
DK (1) DK1362027T3 (de)
EE (1) EE200300370A (de)
ES (1) ES2304432T3 (de)
HR (1) HRP20030645A2 (de)
HU (1) HUP0303133A3 (de)
IL (2) IL157211A0 (de)
MX (1) MXPA03006893A (de)
MY (1) MY136316A (de)
NO (1) NO328767B1 (de)
NZ (1) NZ527471A (de)
PE (1) PE20020870A1 (de)
PL (1) PL363639A1 (de)
PT (1) PT1362027E (de)
PY (1) PY0202851A (de)
RU (1) RU2301797C2 (de)
SK (1) SK10092003A3 (de)
UY (1) UY27165A1 (de)
WO (1) WO2002064546A2 (de)
YU (1) YU64203A (de)
ZA (1) ZA200305414B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
PE20020870A1 (es) * 2001-02-13 2002-11-18 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
US7176310B1 (en) * 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
EP1388342A1 (de) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylierte, Heteroaryl-kondensierte Cycloalkenylamine und deren Verwendung als Arzneimittel
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7105513B2 (en) * 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7132536B2 (en) * 2003-04-24 2006-11-07 Sanofi-Aventis Deutschland Gmbh Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
ES2386354T3 (es) 2003-07-29 2012-08-17 Xenon Pharmaceuticals Inc. Derivados de piridilo y su uso como agentes terapéuticos
EP1529525A1 (de) * 2003-11-06 2005-05-11 Aventis Pharma Deutschland GmbH ENOS Transkriptionsenhancer zur Zellentherapie-Behandlung von Ischämischer Herzerkrankungen
US8309608B2 (en) * 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
EP1568698A1 (de) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrolderivate als faktor-xa-inhibitoren
JP2007277096A (ja) * 2004-07-15 2007-10-25 Astellas Pharma Inc フェネチルニコチンアミド誘導体含有医薬
TW200628159A (en) * 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp IL-12 modulatory compounds
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
EP1741709A1 (de) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl substituierte Amide mit gesättigtem Linker, und deren Verwendung als Pharmaka
EP1741708A1 (de) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl substituierte Amide mit ungesättigtem oder zyklischem Linker, und deren Verwendung als Pharmaka
SI1999114T1 (sl) 2006-03-22 2015-10-30 F. Hoffmann-La Roche Ag Pirazoli kot 11-beta-hsd-1
EP1905764A1 (de) 2006-09-30 2008-04-02 Sanofi-Aventis Substituierte 2-Phenylbenzimidazole und ihre Verwendung als Pharmazeutika
EP1923062A1 (de) 2006-11-16 2008-05-21 sanofi-aventis Imidazo[2,1-b]thiazole und ihre Verwendung als Pharmazeutika
EP1942104A1 (de) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropancarbonsäureamide und deren pharmazeutische Verwendung
EP1939180A1 (de) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamide und ihre Verwendung als Arzneimittel für die Stimulation der Expression der endothelialen NO-Synthase
EP1939181A1 (de) * 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituierte Carboxamide und deren Verwendung für die Stimulierung der NO Synthase Expression
EP1964840A1 (de) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridine und deren pharmazeutische Verwendung
EP1964841A1 (de) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine und deren pharmazeutische Verwendung
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012003405A1 (en) 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
NZ609955A (en) 2010-11-09 2015-05-29 Ironwood Pharmaceuticals Inc Sgc stimulators
US20120309796A1 (en) * 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
CN104066731B (zh) 2011-12-27 2016-06-15 铁木医药有限公司 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
SI2970243T1 (sl) 2013-03-15 2020-04-30 Cyclerion Therapeutics, Inc. SGC stimulatorji
MX368585B (es) * 2013-06-03 2019-10-08 Sackner Marvin Dispositivo pasivo de trote simulado.
EP3092231B1 (de) 2013-12-11 2018-06-27 Ironwood Pharmaceuticals, Inc. Sgc-stimulatoren
EP3094327A1 (de) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. Verwendung von sgc-stimulatoren zur behandlung von neuromuskulären störungen
CA2961489A1 (en) 2014-09-17 2016-03-24 Glen Robert RENNIE Sgc stimulators
CA2959757A1 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
BR112019000293A2 (pt) 2016-07-07 2019-04-16 Ironwood Pharmaceuticals, Inc. formas sólidas de um estimulador de sgc
KR102513343B1 (ko) 2016-07-07 2023-03-22 사이클리온 테라퓨틱스, 인크. sGC 자극제의 인 전구약물
CN113924294B (zh) * 2019-05-29 2024-12-06 先正达农作物保护股份公司 杀微生物衍生物
WO2022085023A1 (en) 2020-10-19 2022-04-28 Council Of Scientific & Industrial Research Bioactive benzocycloheptene analogues from himachalenes and its applications
CN120693339A (zh) * 2022-10-25 2025-09-23 Artus治疗股份有限公司 用于增强上皮和/或内皮屏障功能的治疗剂
CN119409797A (zh) * 2025-01-07 2025-02-11 中肽生化有限公司 一种替度鲁肽的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8402275A (en) * 1974-08-26 1977-02-17 Takeda Chemical Industries Ltd Benzocycloheptene derivatives
CH635310A5 (en) * 1977-05-23 1983-03-31 Sandoz Ag Process for preparing novel benzocycloheptene derivatives
DE3807813A1 (de) 1988-03-10 1989-09-21 Thomae Gmbh Dr K Neue benzocycloheptenderivate, diese verbindungen enthaltende arzneimittel und verfahren zu deren herstellung
CZ287969B6 (cs) 1995-08-10 2001-03-14 Astra Pharmaceuticals Limited Amidinový derivát, způsob jeho přípravy, farmaceutický prostředek s jeho obsahem a použití
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
WO2000003746A2 (en) * 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
AUPP891299A0 (en) 1999-02-26 1999-03-25 Fujisawa Pharmaceutical Co., Ltd. New 6-membered cyclic compounds
AUPQ309399A0 (en) 1999-09-28 1999-10-21 Fujisawa Pharmaceutical Co., Ltd. Benzothiazoline derivatives
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
PE20020870A1 (es) 2001-02-13 2002-11-18 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
PE20020856A1 (es) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
US7105513B2 (en) * 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7338956B2 (en) * 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7186735B2 (en) * 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US8309608B2 (en) * 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases

Also Published As

Publication number Publication date
PL363639A1 (pl) 2004-11-29
IL157211A0 (en) 2004-02-19
WO2002064546A2 (en) 2002-08-22
BR0207197A (pt) 2004-07-06
YU64203A (sh) 2006-05-25
ES2304432T3 (es) 2008-10-16
RU2301797C2 (ru) 2007-06-27
AU2002253012B2 (en) 2008-01-24
UY27165A1 (es) 2002-07-31
MXPA03006893A (es) 2004-04-02
IL157211A (en) 2009-05-04
WO2002064546A3 (en) 2002-11-07
HRP20030645A2 (en) 2005-06-30
NO20033566D0 (no) 2003-08-12
RU2003127723A (ru) 2005-03-20
PE20020870A1 (es) 2002-11-18
NZ527471A (en) 2005-02-25
US7709478B2 (en) 2010-05-04
PY0202851A (es) 2004-06-01
NO328767B1 (no) 2010-05-10
US6759412B2 (en) 2004-07-06
AR035431A1 (es) 2004-05-26
US20040225013A1 (en) 2004-11-11
US20030008915A1 (en) 2003-01-09
CA2438324C (en) 2009-07-07
CN1491208A (zh) 2004-04-21
CZ20032134A3 (cs) 2003-10-15
JP2004518720A (ja) 2004-06-24
NO20033566L (no) 2003-10-13
HUP0303133A2 (hu) 2003-12-29
MY136316A (en) 2008-09-30
DK1362027T3 (da) 2008-09-22
HUP0303133A3 (en) 2007-08-28
EP1362027B1 (de) 2008-05-21
KR100975781B1 (ko) 2010-08-17
BG108060A (bg) 2005-01-31
DE60226704D1 (de) 2008-07-03
PT1362027E (pt) 2008-07-11
JP4319836B2 (ja) 2009-08-26
HK1061017A1 (en) 2004-09-03
EE200300370A (et) 2003-10-15
ZA200305414B (en) 2004-05-20
EP1362027A2 (de) 2003-11-19
CN1296346C (zh) 2007-01-24
SK10092003A3 (sk) 2004-01-08
CA2438324A1 (en) 2002-08-22
KR20030077619A (ko) 2003-10-01

Similar Documents

Publication Publication Date Title
DE60226704D1 (de) Acylierte 6,7,8,9-tetrahydro-5h-benzocycloheptenyl-amine und deren pharmazeutische verwendung
NO2023030I1 (no) Apixaban and pharmaceutical acceptable salts thereof
DE50209372D1 (de) Konjugierte polymere enthaltend spirobifluoren-einheiten und deren verwendung
DE60105859D1 (de) Urazil Verbindungen und deren Verwendung
DE60123274D1 (de) Pyrrolcarboxamide und pyrrolcarbothioamide und deren agrochemische verwendungen
ATE381335T1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
DE60138768D1 (de) Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
DE60230868D1 (de) Criptoblockierende antikörper und deren verwendung
DE50200971D1 (de) Konjugierte polymere enthaltend spirobifluoren-einheiten und fluoren-einheiten und deren verwendung
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
ATE448238T1 (de) 3-beta-d-ribofuranosylthiazolo(4,5- delta)pyridimin-nucleoside und ihre verwendung
EE200300369A (et) Atsüülitud indanüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
DE60225214D1 (de) Authentisches Dokument und dessen Herstellungsverfahren
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60230591D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
HUP0303825A3 (en) 1h-benzimidazole and 3h-imidazo-[4,5b]pyridine-derivatives, their use and pharmaceutical compositions containing them
DE60237580D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
ATE524178T1 (de) Acylierte, heteroaryl-kondensierte cycloalkenylamine und deren verwendung als arzneimittel
DE60236099D1 (de) Druckverfahren, druckerzeugnisse und drucksteuerung
DK1250328T3 (da) Dihydro-1,3,5-triazin-aminderivater og terapeutisk anvendelse deraf
ATA13842001A (de) Chitosan-thio-alkyl-amidin konjugate und deren kosmetische sowie pharmazeutische verwendung
DE60224194D1 (de) Arzneizusammensetzungen enthaltend terbinafin und deren verwendung
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
ATE364575T1 (de) Zeolithe und deren verwendung
HUP0400179A3 (en) 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines, their use and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1362027

Country of ref document: EP